Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Yuqin Song, PhD
CONTACT
JW medical JWCAR239
CONTACT
Lead
Peking University Cancer Hospital & Institute
With
JWCAR239 is a CD19/CD20 CAR-T product. By targeting both CD19 and CD20, it is expected to overcome some limitations with CD19 or CD20 single target products. In this study, patients with B B-NHL will be enrolled to receive JWCAR239. PK/PD properties and preliminary efficacy and safety will be evaluated. Each subject will receive JWCAR239 once and is followed up for up to 2 years.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted